DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose

Information source: Biogen
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Relapsing Remitting Multiple Sclerosis

Intervention: Interferon beta-1a (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: Biogen

Official(s) and/or principal investigator(s):
Biogen-Idec Investigator, Principal Investigator, Affiliation: Biogen


This study is to find out if starting at low dose Avonex and slowly increasing to full dose will improve flu like symptoms as a side effect of Avonex treatment.

Clinical Details

Official title: An Open-Label Study to Examine the Difference in Tolerability Associated With Titration Of Dose on Initiation of Avonex therapY (TODAY)

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: To assess the mean severity of episodes of FLS during the 4 week titration phase

Secondary outcome: To assess the mean severity and duration of FLS episodes in post-titration phase


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Diagnosis of clinically-definite relapsing-remitting multiple sclerosis

Exclusion Criteria:

- Any Product Information-specified contraindications to interferon-beta therapy, or

other medical factors which, in the opinion of the investigator, make the subject unsuitable for interferon-beta therapy

- Use of AVONEX, but not other interferon therapies, in the 3 months prior to

randomisation into the study

- A clinically significant infectious illness (e. g., cellulitis, abscess, pneumonia,

septicemia) within 30 days prior to randomisation.

- History of seizure in the 3 months prior to randomisation

- History of suicidal ideation or severe depression within the 3 months prior to


- Other inclusion and exclusion criteria may apply per study protocol

Locations and Contacts

Coordinating Research Site, Malvern, Victoria 3144, Australia
Additional Information

Starting date: June 2007
Last updated: September 2, 2008

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017